Sub Analysis of Eliquis (BMS/Pfizer)in ARISTOTLE trial show consistent reductions in Stroke and bleeding risk

The reductions in stroke or systemic embolism, major bleeding and mortality demonstrated with Eliquis (apixaban) from BMS/Pfizer ,compared to warfarin in the ARISTOTLE trial were consistent across a wide range of stroke and bleeding risk scores in patients with nonvalvular atrial fibrillation. These results of a subanalysis from the ARISTOTLE trial were published today in The Lancet.The subanalysis demonstrated that irrespective of a patient�s risk of stroke or bleeding, treatment with Eliquis resulted in a consistent reduction in stroke or systemic embolism and mortality, compared to warfarin. There were also consistently lower rates of major bleeding and of intracranial bleeding with Eliquis compared with warfarin across all evaluated CHADS2, CHA2DS2VASc, and HAS-BLED score categories. .see ".Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial" -Dr Renato D Lopes MD, Sana M Al-Khatib MD, Prof Lars Wallentin MD, and others -Oct 02, 2012- The Lancet